Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 6/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703886 | 0.90 | HTT (0.36) | HDAC1 | |
| SCHEMBL20034700 | 0.81 | HTT (0.35) | — | |
| SCHEMBL19255837 | 0.81 | TDP1 (0.49) | DRD2 | |
| SCHEMBL19698095 | 0.79 | OPRM1 (0.49) | EPHX1OPRM1OPRD1OPRK1 | |
| SCHEMBL19698130 | 0.79 | OPRM1 (0.49) | EPHX1OPRM1OPRD1OPRK1 | |
| SCHEMBL19703563 | 0.79 | SIGMAR1 (0.35) | — | |
| SCHEMBL19698138 | 0.78 | OPRM1 (0.50) | EPHX1OPRM1OPRD1OPRK1 | |
| SCHEMBL19698143 | 0.75 | OPRM1 (0.45) | EPHX1OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL19698144 | 0.75 | OPRM1 (0.48) | EPHX1OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL19704491 | 0.74 | PTGS1 (0.44) | HDAC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | EPHX1 4394/4885OPRM1 1682/4885OPRD1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.